Avastin meets breast cancer goal

Roche and Genentech issued exultant press releases Monday to spread the news that Avastin extended breast cancer patients' progression-free survival in a new study. The trial had aimed to prove that Avastin could delay tumor growth, so the drug met its primary endpoint. The result is expected to aid the companies' bid to expand Avastin's use against breast cancer. FiercePharma

Post a comment